专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008068577A2 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：WO2008068577A2
公开(公告)日：2008-06-12
申请号：PCT/IB2007003705
申请日：2007-11-30
申请人： GLENMARK PHARMACEUTICALS LTD , SEN NILENDU , MIRAJKAR SUNIL
发明人： SEN NILENDU , MIRAJKAR SUNIL
IPC分类号： A61K9/20
CPC分类号： A61K9/2018 , A61K9/2054
摘要： A solid pharmaceutical composition comprising (a) a diuretic; and (b) an angiotensin-converting enzyme (ACE) inhibitor, wherein about 100% of the particle size of the diuretic pass through a standard 60# mesh screen is disclosed.
摘要翻译：一种固体药物组合物，其包含（a）利尿剂; 和（b）血管紧张素转换酶（ACE）抑制剂，其中约100％的利尿剂粒径通过标准60＃筛网被公开。

2. 发明申请

WO2009150665A1 ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS OF ESCITALOPRAM AND SALTS THEREOF 审中-公开
标题翻译：口服药物的药物组合物及其盐
公开(公告)号：WO2009150665A1
公开(公告)日：2009-12-17
申请号：PCT/IN2009/000291
申请日：2009-05-18
申请人： LUPIN LIMITED , VELHAL, Avinash, Krishnaji , MIRAJKAR, Sunil, Anantrao , KURIL, Virendra, Ramkrupal , DESHPANDAY, Ninad
发明人： VELHAL, Avinash, Krishnaji , MIRAJKAR, Sunil, Anantrao , KURIL, Virendra, Ramkrupal , DESHPANDAY, Ninad
IPC分类号： A61K9/20 , A61K31/343
CPC分类号： A61K9/0056 , A61K31/343
摘要： An orally disintegrating pharmaceutical composition comprising Escitalopram or salts thereof as an active ingredient; diluent (s) selected from the group consisting of cellulose derivatives such as microcrystalline cellulose and the like, mannitol, lactose, dextrose, sorbitol, starch, xylitol, maltose, dicalcium phosphate and their derivatives thereof; disintegrating agent (s) and optionally one or more suitable pharmaceutically acceptable excipient (s).
摘要翻译：一种口服崩解药物组合物，其包含依他普仑或其盐作为活性成分; 甘油醇，乳糖，葡萄糖，山梨糖醇，淀粉，木糖醇，麦芽糖，磷酸二钙及其衍生物等选自微晶纤维素等纤维素衍生物的稀释剂; 崩解剂和任选的一种或多种合适的药学上可接受的赋形剂。

3. 发明申请

WO2008068577A3 PHARMACEUTICAL COMPOSITIONS 审中-公开
公开(公告)号：WO2008068577A3
公开(公告)日：2008-06-12
申请号：PCT/IB2007/003705
申请日：2007-11-30
申请人： GLENMARK PHARMACEUTICALS LIMITED , SEN, Nilendu , MIRAJKAR, Sunil
发明人： SEN, Nilendu , MIRAJKAR, Sunil
IPC分类号： A61K9/20
摘要： A solid pharmaceutical composition comprising (a) a diuretic; and (b) an angiotensin-converting enzyme (ACE) inhibitor, wherein about 100% of the particle size of the diuretic pass through a standard 60# mesh screen is disclosed.

4. 发明申请

WO2010001413A3 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING QUETIAPINE 审中-公开
标题翻译：包含喹硫平的持续释放药物组合物
公开(公告)号：WO2010001413A3
公开(公告)日：2010-08-12
申请号：PCT/IN2009000369
申请日：2009-06-29
申请人： LUPIN LTD , VELHAL AVINASH KRISHNAJI , MIRAJKAR SUNIL ANANTRAO , KURIL VIRENDRA RAMKRUPAL , RAGHAVAN VINEETH , DESHPANDAY NINAD
发明人： VELHAL AVINASH KRISHNAJI , MIRAJKAR SUNIL ANANTRAO , KURIL VIRENDRA RAMKRUPAL , RAGHAVAN VINEETH , DESHPANDAY NINAD
IPC分类号： A61K9/20 , A61K9/28 , A61K31/554
CPC分类号： A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K9/2866 , A61K31/554
摘要： A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material.
摘要翻译：包含奎硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种不可凝胶控释聚合物以及一种或多种药学上可接受的赋形剂的持续释放剂型。包含第一种颗粒的持续释放剂型，所述第一种颗粒包含奎硫平或其药学上可接受的盐，多晶型物，溶剂化物，水合物和一种或多种释放控制材料; 以及包含一种或多种释放控制材料的第二粒化剂，所述释放控制材料与第一粒化剂的一种或多种释放控制材料相同或不同，并且任选喹硫平或其药学上可接受的盐，多晶型物，溶剂化物，水合物。通过第一次和第二次制粒然后研磨制备持续释放剂型的方法; 将第二次造粒之后的所述研磨颗粒与润滑剂混合，然后压制以形成持续释放剂型。包含速释核心的持续释放剂型，所述速释核心包含奎硫平或其药学上可接受的盐，多晶型物，溶剂化物，水合物和一种或多种药学上可接受的赋形剂; 和包含一种或多种不可胶凝控释材料的缓释包衣。

5. 发明申请

WO2010001413A2 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING QUETIAPINE 审中-公开
标题翻译：持续发布包含QUETIAPINE的药物组合物
公开(公告)号：WO2010001413A2
公开(公告)日：2010-01-07
申请号：PCT/IN2009/000369
申请日：2009-06-29
申请人： LUPIN LIMITED , VELHAL, Avinash, Krishnaji , MIRAJKAR, Sunil, Anantrao , KURIL, Virendra, Ramkrupal , RAGHAVAN, Vineeth , DESHPANDAY, Ninad
发明人： VELHAL, Avinash, Krishnaji , MIRAJKAR, Sunil, Anantrao , KURIL, Virendra, Ramkrupal , RAGHAVAN, Vineeth , DESHPANDAY, Ninad
IPC分类号： A61K9/20 , A61K9/28 , A61K31/554
CPC分类号： A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K9/2866 , A61K31/554
摘要： A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material; and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling; blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients; and sustained release coating comprising one or more non-gellable release controlling material.
摘要翻译：包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种不可凝胶释放控制聚合物和一种或多种药学上可接受的赋形剂的持续释放剂型。一种持续释放剂型，其包含包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种释放控制材料的第一颗粒; 和第二制粒剂，其包含与第一制粒的一种或多种释放控制材料相同或不同的一种或多种释放控制材料，以及任选的喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物。通过第一次和第二次造粒然后研磨制备缓释剂型的方法; 在第二次造粒之后将所述研磨的颗粒与润滑剂混合，然后压缩以形成缓释剂型。包含立即释放核心的缓释剂型包含喹硫平或其药学上可接受的盐，多晶型物，溶剂合物，水合物和一种或多种药学上可接受的赋形剂; 以及包含一种或多种不可凝胶释放控制材料的持续释放涂层。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式